| Date | Time | Source | |
| 05/14/2013 | 9:16AM | PRNUS | Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challeng...
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man PR Newswire BLUE BELL, Pa., May... More...>> |
| 05/10/2013 | 4:41PM | PRNUS | Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results PR Newswire BLUE BELL, Pa., May 10, 2013 BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months... More...>> |
| 05/09/2013 | 4:18AM | ZACKS | Narrower than Expected Loss at Infinity - Analyst Blog
Infinity Pharmaceuticals Inc. (INFI) reported a loss of 57 cents per share in the first quarter of 2013 narrower than the Zacks Consensus Estimate of a loss of 67 cents, but wider than the year-ago loss of 40 cents. The narrower-than-expected loss was primarily due to lower operating expenses incurred by the company in... More...>> |
| 04/19/2013 | 11:00AM | ZACKS | Inovio Reports Promising Data - Analyst Blog
Inovio Pharmaceuticals, Inc. (INO) recently announced encouraging data from a phase I study on its influenza vaccine candidate, SynCon. SynCon is being developed as a universal H1N1 vaccine to protect against several prevalent H1N1 influenza strains. The phase I study, which enrolled 100 healthy volunteers, evaluated SynCon... More...>> |
| 04/18/2013 | 12:00PM | PRNUS | Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vacci...
Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain PR Newswire BLUE BELL... More...>> |
| 04/18/2013 | 4:00AM | PRNUS | Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Cong...
Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013 Biotech recognized for VGX-3100, an innovative therapy for pre-cancers and cancers caused by HPV, now in phase II for cervical dysplasia PR Newswire BLUE BELL, Pa... More...>> |
| 04/10/2013 | 9:00AM | PRNUS | Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device Inovio to Advance Painless Device to Simultaneously Deliver Multiple Vaccines Using Electroporation Technology PR Newswire BLUE BELL, Pa., April 10, 2013 BLUE BELL, Pa., April 10, 2013 /PRNewswire/ -- Inovio... More...>> |
| 04/03/2013 | 8:40AM | MWUS | Fannie Mae Sets Goal for the 1st Quarter of 2013 With ZNGA, EDIG, and INO Reports
Fannie Mae (OTCBB:FNMA) released their most recent 8-K filing yesterday that sent the securities to its highest PPS in nearly five years. The stock hit a high of $1.00 per share briefly and finished the trading session at $0.90 up 12.92% on news of $17.2 B in profits for 2012 with a record $7.6 B in the 4th quarter, FNMA... More...>> |
| 04/02/2013 | 4:00AM | PRNUS | Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection Inovio Plans to Initiate Phase I/IIa Study of its Proprietary, Next Generation HCV Therapeutic Vaccine in 2013 PR Newswire BLUE BELL, Pa., April 2, 2013 BLUE BELL, Pa., April 2, 2013 /PRNewswire/... More...>> |
| 03/28/2013 | 4:00AM | PRNUS | Inovio Pharmaceuticals to Present at BioCentury's "Future Leaders in the Biotech Industry" Conference
Inovio Pharmaceuticals to Present at BioCentury's "Future Leaders in the Biotech Industry" Conference PR Newswire BLUE BELL, Pa., March 28, 2013 BLUE BELL, Pa., March 28, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of... More...>> |
| 03/18/2013 | 5:59PM | PRNUS | Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results PR Newswire BLUE BELL, Pa., March 18, 2013 BLUE BELL, Pa., March 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2012. Total revenue... More...>> |
| 03/12/2013 | 4:43PM | PRNUS | Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants PR Newswire BLUE BELL, Pa., March 12, 2013 BLUE BELL, Pa., March 12, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it has closed an underwritten offering of 27,377,266 shares of its common stock and... More...>> |
| 03/07/2013 | 6:00AM | PRNUS | Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants PR Newswire BLUE BELL, Pa., March 7, 2013 BLUE BELL, Pa., March 7, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it has priced an underwritten offering of 27,377,266 shares of its common stock and... More...>> |
| 02/27/2013 | 4:00AM | PRNUS | Inovio Pharmaceuticals to Present at the Cowen & Company Health Care Conference
Inovio Pharmaceuticals to Present at the Cowen & Company Health Care Conference PR Newswire BLUE BELL, Pa., Feb. 27, 2013 BLUE BELL, Pa., Feb. 27, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced that CEO Dr. J. Joseph Kim will present an overview of the company at the Cowen & Company... More...>> |
| 02/11/2013 | 7:00AM | PRNUS | Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com Company invites individual and institutional investors to log-on to view presentation PR Newswire NEW YORK, Feb. 11, 2013 NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT:... More...>> |
| 02/05/2013 | 8:00AM | PRNUS | Life Sciences and Healthcare Companies Join to Webcast Live on February 7th at RetailInvestorConferences.com
Life Sciences and Healthcare Companies Join to Webcast Live on February 7th at RetailInvestorConferences.com /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;... More...>> |
| 02/05/2013 | 7:00AM | PRNUS | Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial";... More...>> |
| 02/04/2013 | 4:00AM | PRNUS | Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black;... More...>> |
| 01/09/2013 | 4:00AM | PRNUS | Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;... More...>> |
| 01/07/2013 | 4:00AM | PRNUS | PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner to Accelerate Development of Malaria Vaccines and Innovati...
PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner to Accelerate Development of Malaria Vaccines and Innovative Delivery Technologies /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial";... More...>> |
